Izaura Maria Vieira Cayres Vallinoto

Dr. Izaura Maria Vieira Cayres Vallinoto


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Human Immunology
Verified
Journal Article
Closed access
Antonio VallinotoAntonio Vallinoto
Antonio Vallinoto
EGEdnelza S. Graça
Ednelza S. Graça
MAMauro S. Araújo
Mauro S. Araújo
VAVânia N. Azevedo
Vânia N. Azevedo
IVIzaura Maria Vieira Cayres Vallinoto
Izaura Maria Vieira Cayres Vallinoto
RIRicardo Ishak
Ricardo Ishak

17 March 2011 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
EPE.P. Pires
E.P. Pires
CBC.V. Bernardino‐Vallinoto
C.V. Bernardino‐Vallinoto
DAD.M. Alves
D.M. Alves
SMS.R.C. Migone
S.R.C. Migone
LMLuiz Fernando Almeida Machado
Luiz Fernando Almeida Machado
Antonio VallinotoAntonio Vallinoto
Antonio Vallinoto

22 May 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
IBIsabel Luís Jocene Braço
Isabel Luís Jocene Braço
KSKeyla Sá
Keyla Sá
MWMishelle Waqasi
Mishelle Waqasi
MQMARIA ALICE QUEIROZ
MARIA ALICE QUEIROZ
ASAndréa Nazaré Monteiro Rangel da Silva
Andréa Nazaré Monteiro Rangel da Silva
Antonio VallinotoAntonio Vallinoto
Antonio Vallinoto
Studies have shown that the human T-lymphotropic virus 2 (HTLV-2) is endemic in several indigenous populations of the Brazilian Amazon and molecular analyses have shown the exclusive presence of HTLV-2 subtype 2c among the indigenous groups of this geographical region. The present study characterizes the prevalence of HTLV-2 infection in three new villages of the Xikrin tribe, in the Kayapo group, according to their distribution by sex and age. The study included 263 samples from individuals from the Kateté, Djujeko and Oodjã villages. Plasma samples were tested for the presence of anti-HTLV-1/2 antibodies using enzyme-linked immunosorbent assays (ELISA). Seropositive samples were confirmed using real-time PCR, nested PCR and sequencing. The serological and molecular results confirmed the sole presence of HTLV-2 in 77 (29%) samples, with a prevalence of 38% among women and 18% among men. In these communities, it was found that the prevalence of HTLV-2 infection increased with age. Nucleotide sequences (642 bp, 5’LTR) from eight samples were subjected to phylogenetic analysis by the neighbor-joining method to determine the viral subtype, which confirmed the presence of HTLV-2c. The results of the present study establish the presence of HTLV-2 infection in three new villages of the Xikrin tribe and confirm the high endemicity of the infection in the Kayapo indigenous group of the Brazilian Amazon.

21 December 2022 in Viruses
Verified
Journal Article
Open access
PDF file
IAIsabella Nogueira Abreu
Isabella Nogueira Abreu
CLCarlos Neandro Cordeiro Lima
Carlos Neandro Cordeiro Lima
ESEliene Rodrigues Putira Sacuena
Eliene Rodrigues Putira Sacuena
FLFelipe Teixeira Lopes
Felipe Teixeira Lopes
KTKaroliny Torres
Karoliny Torres
Antonio VallinotoAntonio Vallinoto
Antonio Vallinoto
HTLV-1/2 infection is endemic in Indigenous peoples of the Americas. Its origin is attributed to the migratory flow of Amerindian ancestral peoples. The present study aimed to investigate the seroprevalence of HTLV-1/2 infection in Indigenous peoples of the Brazilian Amazon. A total of 3350 Indigenous people belonging to 15 communities were investigated. The investigation was performed using serological (ELISA), molecular (qPCR) and confirmatory (Western blot and/or Inno-Lia) tests to detect and differentiate the infection. The seroprevalence was 8.3% for HTLV-1/2 infection, with 0.1% of individuals seropositive for HTLV-1 and 8.1% for HTLV-2. The prevalence of infection was statistically higher in women (10.1%) than in men (6.5%) (p = 0.0002). This female predominance was observed in all age groups; in females the prevalence was significant from 41 years old (p < 0.0001) and in males from 51 years old (p < 0.0001). Here, we present a prevalence of HTLV-1/2 among Indigenous peoples of the Brazilian Amazon. The endemic infection in these groups must reflect the different epidemiological profiles observed in these peoples, such as sexual transmission through rejection of condom use, breastfeeding, especially in cases of cross-breastfeeding, and the high rate of pregnancy in the villages.

19 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
FRFabíola Brasil Barbosa Rodrigues
Fabíola Brasil Barbosa Rodrigues
RSRosilene da Silva
Rosilene da Silva
ESErika Ferreira dos Santos
Erika Ferreira dos Santos
MBMioni Thieli Figueiredo Magalhães de Brito
Mioni Thieli Figueiredo Magalhães de Brito
ASAndréa Luciana Soares da Silva
Andréa Luciana Soares da Silva
ESEduardo José Melo dos Santos
Eduardo José Melo dos Santos
Interleukin-6 has been recognized as a major role player in COVID-19 severity, being an important regulator of the cytokine storm. Hence, the evaluation of the influence of polymorphisms in key genes of the IL-6 pathway, namely IL6, IL6R, and IL6ST, may provide valuable prognostic/predictive markers for COVID-19. The present cross-sectional study genotyped three SNPs (rs1800795, rs2228145, and rs7730934) at IL6. IL6R and IL6ST genes, respectively, in 227 COVID-19 patients (132 hospitalized and 95 non-hospitalized). Genotype frequencies were compared between these groups. As a control group, published data on gene and genotype frequencies were gathered from published studies before the pandemic started. Our major results point to an association of the IL6 C allele with COVID-19 severity. Moreover, IL-6 plasmatic levels were higher among IL6 CC genotype carriers. Additionally, the frequency of symptoms was higher at IL6 CC and IL6R CC genotypes. In conclusion, the data suggest an important role of IL6 C allele and IL6R CC genotype on COVID-19 severity, in agreement with indirect evidence from the literature about the association of these genotypes with mortality rates, pneumonia, and heightening of protein plasmatic levels pro-inflammatory driven effects.

1 July 2025 in Biology
Verified
Journal Article
Open access
PDF file
KTKaroliny Torres
Karoliny Torres
GNGabriel dos Santos Pereira Neto
Gabriel dos Santos Pereira Neto
IVIzaura Maria Vieira Cayres Vallinoto
Izaura Maria Vieira Cayres Vallinoto
Leonardo O. ReisLeonardo O. Reis
Leonardo O. Reis
Antonio VallinotoAntonio Vallinoto
Antonio Vallinoto
Oncogenic viruses are infectious agents that can cause cancer in humans and animals. They are estimated to be responsible for approximately 12% of human cancers worldwide. These viruses trigger a series of mechanisms that allow them to insert their genetic material into host cells, disrupting normal cellular processes and leading to uncontrolled growth and tumor formation. This article reviews the literature on the main oncogenic viruses and reports on newly identified viruses potentially associated with cancer development, addressing the mechanisms of oncogenesis and the types of cancers associated. In addition, the article brings together the evidence for preventive strategies, such as vaccination, and therapeutic advances in combating oncogenic viral infections. This review discusses the role of early detection and treatment in managing virus-related cancers globally. This article reviews current prevention and treatment strategies, including HPV and HBV vaccines and antiviral therapies, and mentions future approaches like immunotherapies and CRISPR/Cas9. Therefore, this article underscores the importance of studying the dynamics of co-infection and the role of human microbiota in viral persistence and carcinogenesis, which opens new possibilities for combination therapies and microbiome-based interventions to slow the progression of viral-related tumors.